Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study

AstraZeneca completes global licence agreement for Zegfrovy

AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU for first-line HER2-positive metastatic breast cancer

Formosa Pharmaceuticals submits Clinical Trial Application to European regulatory authorities for TSY-110

Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial

DualityBio agrees global collaboration and licensing deal with Genentech

Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit

Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic GEA eligible for ZIIHERA

Daiichi Sankyo and AstraZeneca launch phase 3 trial of Datroway in high-risk bladder cancer

Inify Laboratories launches UK operations with first NHS agreement

Senhwa completes enrolment in Phase 1b expansion trial of CX-5461

McKesson to acquire Precision Medicine Group for approximately USD2.25bn

BreakBio set to enter clinic

Astellas doses first patient in Phase 3 study of ASP2138

Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe